Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | WNT1 | P04628 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | CLK3 | P49761 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175325 | 0.88 | UBE2T (0.56) | RAB9ASMN1; SMN2PARP1HRH3NPC1 | |
| SCHEMBL5638622 | 0.87 | RAB9A (0.60) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL21776925 | 0.84 | RAB9A (0.59) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL24592171 | 0.84 | HRH3 (0.48) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL7679197 | 0.84 | ALDH1A1 (0.66) | RAB9ASMN1; SMN2PARP1HRH3HDAC10 | |
| SCHEMBL6117108 | 0.83 | RAB9A (0.58) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL1329870 | 0.83 | RAB9A (0.58) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL30665072 | 0.83 | RAB9A (0.58) | RAB9AL3MBTL1SMN1; SMN2HDAC2HDAC3 | |
| SCHEMBL5759243 | 0.83 | HRH3 (0.59) | RAB9ASMN1; SMN2PARP1HRH3NPC1 | |
| Hydrochloric Acid SCHEMBL26633196 | 0.83 | HPGDS (0.55) | RAB9AHDAC2HDAC3PARP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023649-A1 | ANDROGEN RECEPTOR BINDING BIFUNCTIONAL MOLECULES | Industrial Technology Research Institute (TW) | 2022-07-06 | — | — | EP | disclosed |
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1856052-B1 | NK1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-7176205-B2 | Bi-pyridinyl derivatives as NK-1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176205-B2 | Bi-pyridinyl derivatives as NK-1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1142144-C | 4-phenyl pyridine derivatives | - | 2004-03-17 | — | — | CN | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| CN-1270959-A | 4-phenyl pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2000-10-25 | — | — | CN | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | RAB9A 2854/4885L3MBTL1 1978/4885SMN1; SMN2 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.